Table 1 Study characteristics and quality of included studies (ordered by year of study)

From: Markers for the non-invasive diagnosis of mesothelioma: a systematic review

   

Quality assessment a

First author-year

Study design

Index test

1a

1b

2

3

4

5

6

7

8a

8b

9

10

11

12

13

Studying serum or effusion markers

 Aleman – 2009r1

Case–control

SMRP(e)

2

2

1

1

3

2

1

1

1

1

2

1

1

1

1

 Davies – 2009r2

Prospective cohort of consecutive patients with pleural effusion, suspected of pleural malignancy

SMRP(e)

2

1

1

1

3

2

1

1

1

1

2

1

1

1

1

 Grigoriu – 2009r3 b

Cohort of patients with suspected mesothelioma

HA(es)

1

1

1

1

3

1

1

1

1

2

1

1

3

1

2

 Rodriquez Portal – 2009r4

Prospective case–control

SMRP(s)

2

1

1

1

3

2

1

1

1

1

2

1

1

1

1

 Shigematsu – 2009r5

Case–control

Gene-X(s), THBS-2(s)

2

2

2

1

3

2

1

1

1

1

2

1

1

1

1

 Amati – 2008r6

Prospective case–control

80HdG(s), HGF(s), PDGFβ(s), SMRP(s), VEGFβ(s), bFGF(s)

2

1

1

1

3

2

1

1

1

2

2

1

1

1

1

 Creaney – 2008r7

Case–control

MPF(s), SMRP(s), osteopontin(s)

2

1

2

1

3

2

1

1

1

2

2

1

1

1

2

 Iwahori – 2008r8

Case–control

MPF(s), SMRP(s)

2

2

2

1

3

2

1

1

1

1

2

1

1

1

1

 Pass – 2008r9

Case–control

SMRP(es)

2

1

2

1

3

2

1

1

1

1

2

1

1

1

2

 Schneider – 2008r10

Prospective case–control

SMRP(s)

2

1

2

1

3

2

3

1

1

1

2

1

3

1

1

 Creaney – - 2007r11 b

Case–control

CA125(s)

2

2

2

1

2

2

1

1

1

1

1

1

1

1

1

 Creaney – 2007r12 c

Retrospective cohort of consecutive patients with pleural effusion

SMRP(e)

2

1

1

1

3

1

1

1

1

1

2

1

1

1

2

 Cristaudo – 2007r13

Case–control

SMRP(s)

2

1

2

1

3

2

1

1

1

1

2

1

1

1

1

 Di Serio – 2007r14

Case–control

SMRP(s)

2

1

2

1

3

2

3

1

1

1

2

1

3

1

1

 Grigoriu – 2007r15 b

Case–control

Osteopontin(s)

2

1

1

1

3

1

1

1

1

2

2

1

3

1

2

 Shiomi – 2007r16

Prospective case–control

MPF(s)

2

1

1

1

3

2

1

1

1

1

1

1

1

1

1

 Van den Heuvel – 2007r17

Retrospective case–control

CEA(s), CYFRA21-1(s), SMRP(s)

2

1

1

1

3

2

1

1

1

1

2

1

1

1

1

 Welker – 2007r18

Case–control

HA(e)

2

2

2

2

3

2

1

1

1

1

1

1

3

1

1

 Onda – 2006r19

Retrospective case–control

MPF(s)

2

1

2

1

3

2

1

1

1

1

2

1

1

1

1

 Filiberti – 2005r20

Prospective case–control

PDGF-AB(s)

2

1

2

1

3

2

1

1

1

1

1

1

1

1

1

 Pass – 2005r21

Case–control

Osteopontin(s)

2

1

1

1

3

2

1

1

1

1

1

1

1

1

1

 Scherpereel – 2005r22

Prospective cohort of consecutive patients with suspected or recently diagnosed mesothelioma

SMRP(es)

1

1

1

1

3

1

1

1

1

1

2

1

3

1

1

 Neri – 2003r23

Prospective case–control

p53(s)

2

1

1

1

3

1

1

1

1

1

2

1

1

1

1

 Villena – 2003r24

Prospective cohort of patients with pleural effusion

CA15-3(e), CA549(e), CA72-4(e), CEA(e)

2

1

1

1

3

3

1

1

1

1

1

1

1

1

1

 Creaney - 2001r25

Case–control

p53(s)

2

2

2

1

3

2

1

1

1

1

2

1

1

1

1

 Paganuzzi – 2001r26

Cohort of consecutive patients with pleural effusion

CEA(e), CYFRA21-1(e)

2

2

2

1

3

1

3

1

1

1

2

1

3

1

1

 Fuhrman – 2000r27

Prospective case–control

CEA(es), HA(e)

2

2

2

1

3

2

1

1

1

1

2

1

1

1

2

 Alatas – 1999r28

Case–control

CA15-3(es), CA19-9(e), CEA(es), CYFRA21-1(es), NSE(es), TSA(es)

2

1

2

1

3

2

1

1

1

1

2

1

1

1

1

 Miedouge – 1999r29

Retrospective case–control

CA15-3(e), CA19-9(e), CA72-4(e), CEA(e), CYFRA21-1(e), NSE(e), SCC(e)

2

2

1

1

3

2

3

1

1

1

1

1

1

1

1

 Nisman – 1998r30

Case–control

CEA(s), CYFRA21-1(s), TPS(s)

2

2

2

1

3

2

1

1

1

1

1

1

1

1

1

 Atagi – 1997r31

Prospective cohort of consecutive patients with pleural effusion or previously diagnosed mesothelioma

CEA(e), HA(e)

2

2

1

1

3

1

3

3

1

1

1

1

3

1

2

 Ebert – 1997r32

Prospective case–control

CEA(s), CYFRA21-1(s), NSE(s), TPA-M(s), TPS(s)

2

2

2

1

3

2

1

1

1

1

1

1

1

1

2

 Shijubo – 1995r33

Case–control

CEA(e), SP-A(e)

2

2

2

1

3

2

1

1

1

1

2

1

1

1

1

 Villena – 1995r34

Prospective cohort of patients with pleural effusion

CA15-3(e), CA19-9(e), CA72-4(e), CEA(e)

2

1

1

1

3

3

1

1

1

1

2

1

1

1

1

 Whitaker – 1986r35

Retrospective case–control

CEA(e)

2

2

2

1

3

2

1

1

1

1

1

1

1

1

1

 Fravelli – 1984r36

Cohort of patients with pleural effusion

CEA(e)

2

1

2

1

3

3

1

1

1

1

1

1

1

1

1

Studying immunohistochemical markers

 Shen – 2009r37

Retrospective case–control

EMA, Glut-1m, Glut-1p, XIAP

2

2

2

1

3

2

3

3

1

2

2

1

1

3

1

 Slipicevic – 2009r38

Case–control

IGF-II, IGFBP3

2

2

2

1

3

2

3

3

1

2

2

3

3

3

1

 Yuan – 2009r39

Case–control

B72-3, Ber-EP4, EMA, Tenascin-X, calretinin

2

2

2

1

3

2

1

1

1

2

2

3

1

3

1

 Bhalla – 2007r40

Retrospective case–control

CK5, D2-40, calretinin, podoplanin

2

2

2

1

3

2

1

1

1

2

2

3

1

3

1

 Facchetti – 2007r41

Retrospective cohort of patients with effusion

Claudin4

2

2

2

1

3

2

1

1

1

1

1

3

1

3

1

 Grefte – 2007r42

Retrospective case–control

B72-3, Ber-EP4, CEA, EMA, HMFG-2, calretinin

2

2

2

1

3

2

3

3

1

2

2

1

3

2

1

 Kleinberg – 2007r43

Retrospective case–control

Claudin1, claudin3

2

2

2

1

3

2

1

1

1

2

2

3

1

3

1

 Pu – 2007r44

Retrospective case–control

MOC-31, WT-1, mesothelin, p63

2

2

2

1

3

2

1

1

1

2

2

1

1

3

2

 Shield – 2007r45

Retrospective case–control

CK5/6, calretinin

2

2

2

1

3

2

2

3

1

2

1

3

2

3

1

 Aerts – 2006r46

Prospective case–control

Ber-EP4, CEA, EMA, TAG-72

2

2

2

1

3

2

3

3

1

2

2

1

3

2

1

 Bassarova – 2006r47

Case–control

D2-40

2

2

2

1

3

2

3

3

1

2

2

3

3

3

1

 Li – 2006r48

Retrospective case–control

Ber-EP4, CAM5-2, CEA, CK5/6, K903, calretinin

2

2

2

1

3

2

3

3

1

2

2

3

3

3

1

 Saad – 2006r49

Retrospective case–control

CK5/6, D2-40, TTF-1, WT-1, calretinin, p63

2

2

2

1

3

2

3

1

1

2

1

1

3

2

1

 Sivertsen – 2006r50

Case-control

E-cadherin, N-cadherin, P-cadherin

2

2

2

1

3

2

3

3

2

2

2

3

3

3

1

 Afify – 2005r51

Retrospective case–control

CD44S, HA

2

2

2

1

3

2

1

1

1

2

1

3

1

3

1

 Hecht – 2005r52

Retrospective case–control

MOC-31

2

2

2

2

3

2

1

1

1

2

2

3

1

3

1

 Saad – 2005r53

Retrospective case–control

EMA

2

2

2

1

3

2

1

1

1

1

2

1

1

2

1

 Saqi – 2005r54

Case–control

CD138

2

2

2

1

3

2

1

1

1

1

2

3

1

3

1

 Schonherr – 2004r55

Case–control

Ki67

2

2

2

1

3

2

1

1

1

1

1

3

1

3

1

 Afify – 2002r56

Retrospective case–control

TTF-1

2

2

2

1

3

2

1

1

1

2

1

3

1

3

1

 Afify – 2002r57

Retrospective case–control

Actin, desmin, myogenin, myoglobin

2

2

2

1

3

2

1

1

1

2

1

3

1

3

1

 Davidson – 2001r58 b

Case–control

CA125, CEA, desmin, p53, vimentin

2

2

2

1

3

2

1

2

1

2

1

1

2

1

1

 Hecht – 2001r59

Retrospective case–control

WT1

2

2

2

1

3

2

3

3

1

2

2

3

3

3

1

 Hecht – 2001r60

Retrospective case–control

TTF-1

2

2

2

1

3

2

1

1

1

2

2

3

1

3

1

 Simsir – 2001r61

Retrospective case–control

SV-40

2

2

2

3

2

2

1

1

1

2

2

3

1

3

1

 Wieczorek – 2000r62

Retrospective case–control

Calretinin

2

2

2

1

3

2

1

1

1

1

1

1

1

2

1

 Dejmek – 1999r63

Retrospective case–control

CAM5-2, Leu-M1

2

2

2

1

3

2

2

3

1

2

2

3

3

3

2

 Motherby – 1999r64

Retrospective cohort of patient with pleural effusion

Ber-EP4, CEA, EMA, Leu-M1

2

2

2

3

3

2

2

2

1

2

2

3

2

3

2

 Simir – 1999r65

Retrospective case–control

E-cadherin, N-cadherin, calretinin

2

2

2

3

3

2

1

1

1

2

2

3

1

3

1

 Ascoli – 1997r66

Case–control

HBME-1

2

2

2

1

3

2

2

3

1

2

1

3

3

3

1

 Delahaye – 1997r67

Case–control

B72-3, Ber-EP4, CEA, Leu-M1, MOC-31

2

2

2

1

3

2

3

3

1

2

2

3

3

3

1

 Ascoli – 1995r68

Case–control

Ber-EP4, EMA, cytokeratin, thrombomodulin

2

2

2

1

3

2

2

3

1

2

1

3

3

3

1

 Baars – 1994r69

Retrospective case–control

Keratin7

2

2

2

1

3

2

1

1

1

2

2

3

1

3

1

 Donna – 1992r70

Case–control

Mesothelin

2

2

2

1

3

2

2

1

1

1

2

3

3

3

1

 Betta – 1991r71

Case–control

B72-3

2

2

2

1

3

2

3

1

1

2

2

3

3

3

1

 Delahaye – 1991r72 b

Retrospective case–control

EMA, OV632

2

2

2

1

3

2

1

1

1

2

2

3

1

3

1

 Kuhlman – 1991r73

Retrospective case–control

B72-3, BMA-120, Ber-EP4, CEA, HEA-125, cytokeratin, vimentin

2

2

2

1

3

2

1

1

1

2

2

3

1

3

1

 Linari – 1989r74

Prospective case–control

HMFG-2

2

2

2

3

3

2

2

3

1

2

2

3

2

3

1

 Cibas – 1987r75

Retrospective case–control

CEA, EMA, HMFG-2, keratin

2

1

2

1

3

2

1

1

1

2

2

3

1

3

1

 Ghosh – 1987r76

Retrospective cohort of patients with suspected/diagnosed mesothelioma

CA1/2, CEA, HMFG-2

1

2

2

1

3

2

1

1

1

2

2

3

1

3

1

 Walts – 1983r77

Retrospective case–control

Keratin

2

2

2

1

3

2

3

1

1

2

1

3

3

3

1

Studying genetic markers

 Illei – 2003r78

Prospective case–control

CDKN2A-deletion(e)

2

1

2

1

3

2

3

1

1

1

2

3

3

3

1

 Flores-Staino – 2009r79

Case–control

CDKN2A-deletion(e)

2

2

2

1

3

2

1

1

1

1

2

3

1

3

1

Studying several types of markers

 Botelho – 2008r80

Retrospective case–control

Genetic: CDKN2A-deletion(e) immunohistochemical: Ber-EP4, calretinin

2

2

2

2

3

2

2

1

1

2

2

3

2

3

1

 Creaney – 2008r81

Retrospective case–control

Biomarkers: CA15-3(es) immunohistochemical: EMA

2

2

2

1

3

2

3

3

1

1

2

3

3

3

2

 Dejmek – 2005r82

Case–control

Biomarkers: HA(e) immunohistochemical: Ber-EP4, CEA, Ca125, EMA, HBME-1, Sial-Tn, thrombomodulin, vimentin

2

2

2

1

3

2

2

1

1

1

2

3

3

3

2

  1. (e), assessed in effusion; (s), assessed in serum; (es), assessed in effusion and serum.
  2. aSee Supplementary Appendix for criteria on quality assessment, items were scored 1=yes, 2=no, 3=unclear.
  3. bAlso studied other markers that we did not incorporate because of overlap with other studies.
  4. cAlso studied SMRP in serum that we did not incorporate because of overlap with other studies.
Back to article page